Drugs / HYDROXYFLUTAMIDE
HYDROXYFLUTAMIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00913263 | Jun 2009 → May 2011 | prostate cancer | Lidds AB | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03348527 | May 2017 → Oct 2020 | prostate cancer | Lidds AB | Completed | No outcome recorded |
| Phase 2 | NCT02341404 | May 2012 → May 2015 | prostate cancer | Lidds AB | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYDROXYFLUTAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL491 ↗ |
| Known as | .alpha.-hydroxyflutamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL491 ↗ |
| Known as | 2-HOF | “A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the...” NCT02341404 ↗1“containing the active drug 2-Hydroxyflutamide (2-HOF.” NCT00913263 ↗ |
| Known as | 2-Hydroxyflutamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03348527 ↗ |
| Modality | Small molecule | — CHEMBL491 ↗ |
| Route | Other | “injected into the prostate” NCT00913263 ↗ |